<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0204634</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5121</journal-id>
<journal-id journal-id-type="nlm-ta">J Pathol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Pathol.</journal-id>
<journal-title-group>
<journal-title>The Journal of pathology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3417</issn>
<issn pub-type="epub">1096-9896</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27753446</article-id>
<article-id pub-id-type="pmc">5167646</article-id>
<article-id pub-id-type="doi">10.1002/path.4827</article-id>
<article-id pub-id-type="manuscript">NIHMS826166</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lam</surname>
<given-names>Hilaire C.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nijmeh</surname>
<given-names>Julie S.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Henske</surname>
<given-names>Elizabeth P.</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<aff id="A1">Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA</aff>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence to: Elizabeth P. Henske, Brigham and Women’s Hospital, 25 Shattuck Street, Boston MA 02115, USA. <email>EHenske@BWH.Harvard.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p>Conflict of interest statement: No potential conflicts of interest to disclose</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>241</volume>
<issue>2</issue>
<fpage>219</fpage>
<lpage>225</lpage>
<!--elocation-id from pubmed: 10.1002/path.4827-->
<abstract>
<p id="P1">In just the past five years, dramatic changes have occurred in the clinical management of Tuberous Sclerosis Complex (TSC). Detailed knowledge about the role of the TSC proteins in regulating the activity of the mammalian Target of Rapamycin Complex 1 (mTORC1) underlies this paradigm-shifting progress. Advances continue to be made in understanding the genetic pathogenesis of the different tumours that occur in TSC, including pivotal discoveries using next-generation sequencing (NGS). For example, the pathogenesis of angiofibromas is now known to involve UV-induced mutations, and the pathogenesis of multifocal renal cell carcinoma (RCC) in TSC is now known to result from distinct second-hit mutations. In parallel, the pathological features of TSC-associated tumours, including TSC-associated renal cell carcinoma, continue to be defined, despite the fact that TSC was first described 180 years ago. Here, we review recent discoveries related to the pathologic features and genetic pathogenesis of TSC-associated tumours.</p>
</abstract>
<kwd-group>
<kwd>Tuberous sclerosis complex (TSC)</kwd>
<kwd>next generation sequencing (NGS)</kwd>
<kwd>mosaicism</kwd>
<kwd>no mutation identified (NMI)</kwd>
<kwd>angiofibroma</kwd>
<kwd>angiomyolipoma (AML)</kwd>
<kwd>renal cell carcinoma (RCC)</kwd>
<kwd>lymphangioleiomyomatosis (LAM)</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>